Adicet Bio IncACET
Price$7.14

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$99MTTM through 30 Jun 2026
Free Cash Flow -$85MTTM through 30 Jun 2026

Margins

Current

Returns

-14.4%ROE
-11.9%ROA

Balance Sheet Health

Debt / Equity0.10x
Current Ratio7.65x
Net Debt-$123.7Mnet cash position
Cash & Equivalents$33.1M

Quality Metrics

Altman Z-Score-5.85
Piotroski F-Score2 / 9
Earnings-Beat Rate75.0%

Multi-Year Trend

Diluted EPS-$10.42TTM
'21'22'23'24'25
FY2025: $-16.95

Dividend

No dividend

Capital Allocation

R&D Spend$83.8M

Segment Performance

SegmentRevenueYoYOutlook
Allogeneic Gamma Delta T Cell Therapies$0
View details

Clinical updates expected in mid-2026 and 2H 2026; regulatory filing for ADI-212 planned for Q3 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.